HUTCHMED (China) Ltd (NAS:HCM)

$ 16.88 -0.66 (-3.76%) Market Cap: 3.08 Bil Enterprise Value: 2.32 Bil PE Ratio: 0 PB Ratio: 4.10 GF Score: 68/100

Half Year 2024 HUTCHMED (China) Ltd Earnings Call Transcript
Jul 31, 2024

$19.44 (+8.00%)

Earnings
Full Year 2023 HUTCHMED (China) Ltd Earnings Call Transcript
Feb 28, 2024

$15.21 (-4.88%)

Earnings
HUTCHMED (China) Ltd at Deutsche Bank ADR Investor Conference (Virtual) Transcript
Nov 09, 2023
Half Year 2023 HUTCHMED (China) Ltd Earnings Call Transcript
Jul 31, 2023

$14.07 (-4.42%)

Earnings
HUTCHMED (China) Ltd at Goldman Sachs Healthcare Conference Transcript
Jun 12, 2023
HUTCHMED (China) Ltd at Jefferies Healthcare Conference Transcript
Jun 08, 2023
HUTCHMED (China) Ltd at Bank of America Global Healthcare Conference Transcript
May 10, 2023
Full Year 2022 HUTCHMED (China) Ltd Earnings Call Transcript
Feb 28, 2023

$16.55 (+5.35%)

Earnings
HUTCHMED (China) Ltd Announces License to Takeda to Develop and Commercialize Fruquintinib Outside China Call Transcript
Jan 23, 2023
HUTCHMED (China) Ltd at OTC Markets and Deutsche Bank dbVIC ADR Virtual Investor Conference Transcript
Nov 17, 2022
HUTCHMED (China) Ltd at Bank of America Precision Oncology Conference Transcript
Oct 03, 2022
HUTCHMED (China) Ltd FRESCO-2 Data at ESMO Call Transcript
Sep 12, 2022
Half Year 2022 HUTCHMED (China) Ltd Earnings Call Transcript
Aug 01, 2022

$12.07 (-7.65%)

Earnings
HUTCHMED (China) Ltd Company Update: Surufatinib FDA NDA Status Corporate Call Transcript
May 02, 2022
Full Year 2021 HUTCHMED (China) Ltd Earnings Call Transcript
Mar 03, 2022

$24.37 (-6.95%)

Earnings
HUTCHMED (China) Ltd at OTC Markets and Deutsche Bank Depositary Receipts Virtual Investor Conference Transcript
Nov 17, 2021
HUTCHMED (China) Ltd and Epizyme Inc Announce Strategic Collaboration to Develop and Commercialize TAZVERIK® in Greater China Call Transcript
Aug 09, 2021
Half Year 2021 HUTCHMED (China) Ltd Earnings Call Transcript
Jul 28, 2021

$41.81 (+14.71%)

Earnings
HUTCHMED (China) Ltd at Goldman Sachs Global Healthcare Conference (Virtual) Transcript
Jun 09, 2021
HUTCHMED (China) Ltd Corporate Call Transcript
May 27, 2021
HUTCHMED (China) Ltd virtual investor update Call Transcript
May 26, 2021
HUTCHMED (China) Ltd at Bank of America Global Research Healthcare Conference (Virtual) Transcript
May 11, 2021
Full Year 2020 Hutchison China MediTech Ltd Earnings Call Transcript
Mar 04, 2021

$27.86 (-7.16%)

Earnings
Hutchison China MediTech Ltd at JPMorgan Healthcare Conference (Virtual) Transcript
Jan 11, 2021
Half Year 2020 Hutchison China MediTech Ltd Earnings Call Transcript
Jul 30, 2020

$26.99 (-3.05%)

Earnings
Hutchison China MediTech Ltd Investor Update at ASCO Transcript
Jun 01, 2020
Hutchison China MediTech Ltd at Bank of America Merrill Lynch Healthcare Conference (Virtual) Transcript
May 14, 2020
Hutchison China MediTech Ltd at PR Newswire and BetterInvesting (NAIC) Deutsche Bank Depositary Receipts Virtual Investor Conference Transcript
Mar 19, 2020
Full Year 2019 Hutchison China MediTech Ltd Earnings Call Transcript
Mar 03, 2020

$24.78 (-0.88%)

Earnings
Hutchison China MediTech Ltd at JPMorgan Healthcare Conference Transcript
Jan 15, 2020
Hutchison China MediTech Ltd at Deutsche Bank Depositary Receipts Virtual Investor Conference Transcript
Nov 13, 2019
Hutchison China MediTech Limited - Special Call Transcript
Sep 30, 2019
Hutchison China MediTech Ltd at Morgan Stanley Healthcare Conference Transcript
Sep 11, 2019
Half Year 2019 Hutchison China MediTech Ltd Earnings Presentation Transcript
Jul 30, 2019
Hutchison China MediTech Ltd at Deutsche Bank Depositary Receipts Virtual Investor Conference Transcript
May 15, 2019
Full Year 2018 Hutchison China MediTech Ltd Earnings Call Transcript
Mar 11, 2019

Earnings
Full Year 2018 Hutchison China MediTech Ltd Earnings Call Transcript
Mar 11, 2019

Earnings

HUTCHMED (China) Ltd Company Update: Surufatinib FDA NDA Status Corporate Call Transcript

May 02, 2022 / 12:00PM GMT

Release Date Price: $12.23 (-18.95%)

Transcript

Operator

Good evening, good afternoon, and good morning. Welcome to the HUTCHMED conference call. (Operator Instructions) Please be advised that this call will be recorded. I will turn the call over to our first speaker today, Mark Lee, Senior Vice President of Corporate Finance and Development. Please go ahead.

Kin Hung Lee;China;Limited;SVP of Corporate Finance;Development

HUTCHMED

()-&

Thanks, Regina. Thank you, everybody, for attending the HUTCHMED conference call today to discuss the FDA update on surufatinib's NDA in neuroendocrine tumors. As most of you know, we issued a press release 2 hours ago detailing this current status, and it's on our website.

This call -- a replay of this call will be available after this concludes. So today, we have on the call our executive management team, Dr. Weiguo Su, Chief Executive Officer and Chief Scientific Officer; Dr. Marek Kania, Managing Director and Chief Medical Officer of HUTCHMED International; Johnny Cheng, our Chief Financial Officer; and Dr

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.